Europska Unija - hrvatski - EMA (European Medicines Agency)

theravia - hidroksikarbamid - anemija, sickle cell - antineoplastična sredstva - Шиклоше je indiciran za prevenciju рецидивирующих boli сосудисто-jamice кризов, uključujući akutni sindrom grudnog koša kod djece i odraslih pacijenata koji boluju od simptomatske anemija srpastih stanica sindrom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - hidroksikarbamid - anemija, sickle cell - antineoplastična sredstva - prevencija сосудисто-jamice komplikacija anemija srpastih stanica anemije u bolesnika starijih od 2 godine.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.